According to the recommendations of the 2023 Focused Update of the 2021 European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure, patients with chronic heart failure should receive SGLT2 inhibitors to reduce hospitalization for heart failure or cardiovascular death (McDonagh et al., 2023). Here, SLC5A2 is linked to heart failure.